Valeant Pharmaceuticals International, Inc. 4

4 · Valeant Pharmaceuticals International, Inc. · Filed Jun 3, 2013

Form 4

Period: 2013-05-30

Director

Transactions

Award
Common Stock, no par value
2013-05-30+3,225→ 26,705 total
Tax Payment
Common Stock, no par value
2013-05-30$90.81/sh−3,873$351,707→ 22,833 total
Disposition to Issuer
Deferred Share Units
2013-05-30−3,225→ 0 total
Exercise: $0.00→ Common Shares, no par value (3,225 underlying)

Footnotes (3)

[F1]On May 30, 2012, upon recommendation of the Nominating and Corporate Governance Committee, the Board determined that it was in the Company's best interest to terminate the equity program of the Mandatory Share Units (other units granted prior to October 3, 2004) and to be delivered in 2013 pursuant to the plan termination rules under Code Section 409A. The unit disposed of here may have previously have been settled for one share of issuer common stock or the cash value, thereof, depending on the terms of the applicable award. The prior deferred share units have been exchanged for an equal amount of common shares.
[F2]This number represents common shares purchased and other equity awards that were previously reported in Table 1.
[F3]This number represents common shares withheld to satisfy certain tax withholding obligations due upon settling of Mandatory Share Units.

Documents

1 file